Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.
Start 7-day free trial → Log in

CERC-301 · MK-0657

Small molecule · developed by Avalo Therapeutics

Phase 2 Most advanced trial (none active)
AVTX Developer
1 Registered trials

What is CERC-301?

CERC-301, also known as MK-0657, is a small molecule studied in major depressive disorder.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as
MK-0657
Drug type
Small molecule
Therapy area
Psychiatry
Developer
Avalo Therapeutics, Inc. (AVTX)
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 2
UNII
5HAM167S5T

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT01941043 Phase 2 Major Depressive Disorder Completed AVTX

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Major Depressive Disorder

More from Avalo Therapeutics

AVTX-002 Phase 2 AVTX-009 Phase 2 Camoteskimab Phase 1 CERC-006 Phase 1 FP01 Phase 2

Follow AVTX, the company behind CERC-301

See AVTX's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

AVTX catalysts and pipeline →
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.